3 Forgotten AI Stocks That Should Rebound From Their Corrections

Penguin Solutions reported 48% year-over-year fiscal Q3 2026 revenue growth, with its AI-focused Integrated Memory segment more than doubling and rising to 57.5% of revenue from 40.1% a year earlier. MaxLinear posted 55% year-over-year Q2 revenue growth and guided to $215 million in Q3 revenue at the midpoint, implying 27% sequential growth, supported by optical AI data-center demand. Aehr Test Systems expects fiscal 2027 revenue of $130 million-$150 million versus $50 million in fiscal 2026 and secured a $22 million follow-on AI-processor testing order, though its $3 billion valuation remains elevated.

Analysis

PENG's upside hinges less on CXL revenue growth than on whether CXL memory pooling becomes a recurring platform layer rather than a one-off systems integration sale. If Integrated Memory carries lower gross margin than the legacy business or requires working-capital-heavy inventory, the revenue mix shift could disappoint despite strong top-line growth. The more direct public CXL beneficiary remains ALAB, so evidence that PENG is winning attach rates in OEM or hyperscaler deployments—not merely participating in early deployments—is required before underwriting multiple expansion.

MXL is the cleanest near-term earnings-revision candidate, but its optical exposure puts it in direct competition with MRVL, COHR, LITE and AAOI. The key second-order issue is component content: AI cluster spending can grow while MXL loses if customers standardize on competing DSP, retimer, or optical-module architectures. Over the next 1-3 months, order visibility and gross-margin progression matter more than management's multiyear framing; a guide raise without margin leverage would signal pricing pressure rather than durable share gains.

AEHR is a high-beta execution story, not a diversified AI infrastructure proxy. Its valuation leaves little room for qualification delays, customer concentration, or order timing volatility, while TER and COHU offer more established test exposure at materially lower single-program risk. The contrarian view is that hyperscaler silicon complexity may favor internal test-capex and larger incumbents, limiting AEHR's addressable market despite strong early interest; verify backlog conversion and repeat-order cadence before treating the forward revenue outlook as bankable.

Key Decisions for Investors

• Initiate a 1-3 month long MXL / short SOXX pair only after the next revenue guide is maintained or raised and gross-margin guidance is stable-to-up; target 15-20% relative upside, with a 7% relative stop if optical revenue decelerates or margins contract.
• Keep PENG on a catalyst watch rather than chase momentum: buy a starter position only if the next filing shows Integrated Memory gross-margin expansion and no material receivable/inventory build. Upside is 20-30% on proof of scalable CXL economics; exit if segment growth remains strong but consolidated cash conversion weakens.
• Avoid directional AEHR at current expectations; consider a tactical short or put spread around results only if backlog, customer concentration, and qualification-to-revenue timing remain undisclosed. A 20-30% downside is plausible on a single order deferral, while a disclosed multi-customer backlog would invalidate the bearish setup.
• Monitor ALAB versus PENG for CXL design-win disclosures and MRVL/COHR/LITE versus MXL for optical content trends. A widening revenue-growth gap in either comparison would identify whether the smaller names have genuine share gains or are simply riding AI capex.